Getting started
Cannabis for Migraines Australia — Evidence, Dosing and Access Guide (2026)
Migraine affects 4.9 million Australians and is one of the most disabling neurological conditions. Medicinal cannabis shows strong promise for migraine prevention and acute relief. A complete evidence-based guide for Australian migraine sufferers in 2026.
Migraine is not just a headache. It is a complex neurological disorder affecting 4.9 million Australians — approximately 18% of women and 6% of men — characterised by recurrent moderate-to-severe headache attacks often accompanied by nausea, vomiting, light sensitivity, sound sensitivity and in many cases aura. Migraine is the second leading cause of years lived with disability globally and the leading cause in women under 50. Conventional treatment leaves many sufferers with inadequate relief. Medicinal cannabis is increasingly used both for migraine prevention and acute attack management.
Why migraine is difficult to treat
Migraine pathophysiology involves multiple systems simultaneously:
- Cortical spreading depression — a wave of neuronal depolarisation that initiates aura and triggers the headache phase
- Trigeminal nerve sensitisation — the trigeminal pain pathway becomes hyperactivated and sensitised during attacks
- Central sensitisation — with repeated attacks, the central nervous system becomes permanently hypersensitive to pain triggers
- Neuroinflammation — inflammatory neuropeptides (CGRP, substance P) are released during attacks, driving vascular changes and pain amplification
The endocannabinoid system has roles in all four of these processes, explaining why cannabis can be therapeutically useful.
How cannabis helps migraines — the mechanisms
Cortical spreading depression inhibition:
Endocannabinoids have demonstrated inhibition of cortical spreading depression in animal models. CB1 receptors in the cortex modulate neuronal excitability, potentially reducing the initiation of migraine attacks.
Trigeminal pain modulation:
CB1 receptors are expressed throughout the trigeminal pain pathway. THC’s CB1 agonism reduces trigeminal sensitisation — the core driver of migraine headache pain. This is why cannabis can abort migraine attacks in progress.
CGRP and neuroinflammation reduction:
CBD reduces the release of CGRP (calcitonin gene-related peptide), the key inflammatory neuropeptide now targeted by the newest class of preventive migraine medications (gepants and CGRP monoclonal antibodies). Cannabis may work by a similar pathway, offering preventive effect.
Serotonin system modulation:
CBD modulates 5-HT1A serotonin receptors — the same receptor targeted by triptans (the most effective acute migraine treatment). This provides an additive or complementary mechanism when cannabis is used alongside triptans.
Central sensitisation reduction:
Regular cannabis use appears to reduce central sensitisation over time, potentially explaining the preventive effect observed in migraine sufferers who use cannabis regularly.
Evidence for cannabis in migraine
2019 Washington State University study: Analysis of 12,000 cannabis use sessions by migraine sufferers showed that cannabis reduced headache severity by approximately 50% in acute use. Concentrated (inhaled) cannabis reduced headaches by 51%; CBD-dominant products reduced headaches by 25%. Overuse headache was not a significant problem at standard cannabis doses.
2020 Colorado retrospective study: Adults using cannabis reported a 50% reduction in monthly migraine frequency compared to pre-cannabis baseline. This preventive effect matches or exceeds that of first-line preventive medications (topiramate, valproate, propranolol) in real-world comparison.
2021 Journal of Pain Research review: Systematic review concludes that cannabis “likely reduces the frequency and severity of migraine” based on available evidence, with a call for RCTs that are now underway.
Limitations: Large placebo-controlled RCTs specifically for migraine are limited. The available data is primarily observational with inherent selection bias. Cannabis should be positioned as a complementary therapy — not a first-line replacement for evidence-based migraine treatment — pending more robust controlled data.
Preventive vs acute use — different approaches
Prevention (daily/regular use)
- Goal: Reduce monthly attack frequency
- Best product: CBD-dominant oil, taken morning and/or evening
- Dose range: CBD 20–100mg/day; start low and titrate
- Why: CBD’s CGRP-modulatory, serotonin and anti-inflammatory effects reduce attack triggers when used consistently
- Timeline: Allow 4–8 weeks of consistent use to assess preventive effect
- Terpenes: Caryophyllene (anti-inflammatory), linalool (anti-anxiety), limonene (anti-stress)
Acute (at attack onset)
- Goal: Abort the migraine attack or reduce severity/duration
- Best product: Inhaled flower/vapour (fastest onset — 2–5 minutes) or sublingual oil (15–30 minutes)
- Dose: Low-to-moderate THC (2–5mg) at migraine onset, before full attack establishes
- Why: THC’s CB1 trigeminal pain modulation is most effective before central sensitisation fully establishes (the “window of opportunity” at attack onset)
- Best strains for acute use: Caryophyllene-dominant hybrids (OG Kush, GSC, AK-47); avoid very high-THC products as they can worsen nausea
- Note: Cannabis can also be used alongside triptans — discuss with your prescriber
Cannabis for chronic migraine and medication overuse headache
Chronic migraine (≥15 headache days/month) is where cannabis may offer the most significant benefit:
Medication overuse headache (MOH) — also called rebound headache — develops when acute pain medications (including triptans, NSAIDs and opioids) are used more than 10–15 days/month. MOH is extremely common in chronic migraine and creates a cycle where the medication itself perpetuates headaches.
Cannabis does not appear to cause medication overuse headache at standard medicinal doses — a significant advantage over conventional acute treatments. Some Australian prescribers specifically use cannabis as an MOH-sparing strategy, allowing patients to reduce triptan/NSAID frequency while maintaining acute relief.
For cluster headaches (a separate but related condition):
Anecdotal evidence for cannabis in cluster headaches is positive, though controlled evidence is limited. CBD-dominant products for prevention and low-dose THC for acute cluster attack have been used by Australian prescribers.
Product recommendations for migraine
| Use case | Product type | Key terpenes |
|---|---|---|
| Daily prevention | CBD oil (sublingual) | Caryophyllene, linalool |
| Acute attack (fast onset) | Indica flower (vaporised) | Myrcene, caryophyllene |
| Acute with nausea | Sublingual oil (avoids inhaling) | Caryophyllene, linalool |
| Sleep disruption | Indica THC oil (evening) | Myrcene, linalool |
| Anxiety-triggered migraine | CBD:THC balanced oil | Linalool, limonene |
Avoid: Very high-THC products during acute attacks with nausea — high THC can worsen nausea and induce cannabinoid hyperemesis in sensitive individuals. Start low.
Drug interactions with migraine medications
| Medication | Cannabis interaction | Guidance |
|---|---|---|
| Triptans (sumatriptan, rizatriptan) | Complementary mechanism; generally safe | Can be used together; may allow lower triptan doses |
| Beta-blockers (propranolol — preventive) | Additive blood pressure lowering possible | Monitor blood pressure; start cannabis at low dose |
| Topiramate (preventive) | CBD may increase topiramate levels via CYP2C19 | Inform prescriber; monitor for topiramate side effects |
| Valproate (preventive) | No significant known interaction | Generally safe to combine |
| NSAIDs (acute) | Generally safe combined | Cannabis may allow NSAID dose reduction |
| Opioids (acute — severe migraine) | Additive sedation | Only under prescriber guidance |
Accessing medicinal cannabis for migraine in Australia
Migraine is an accepted TGA SAS-B indication, particularly for chronic migraine and treatment-resistant cases.
- Document your migraine history — frequency, severity, treatments tried and their effectiveness. A headache diary from the past 2–3 months strengthens the TGA application
- Book a telehealth consultation — several Australian medicinal cannabis platforms have prescribers experienced in migraine and headache disorders
- TGA SAS-B approval — typically granted within 24–48 hours
- Start with CBD-dominant prevention — then add low-dose THC for acute use as needed
Frequently asked questions — cannabis for migraines
Does cannabis stop migraines?
Evidence strongly suggests cannabis can both reduce migraine frequency (preventive) and reduce severity during attacks (acute). It is not curative, but many Australian patients achieve 40–60% reduction in attack frequency with regular CBD use, comparable to first-line preventive medications.
Is CBD or THC better for migraine?
Both have roles. CBD is preferred for daily prevention — it provides anti-inflammatory and CGRP-modulatory effects without psychoactivity. THC provides faster, stronger acute pain relief — useful at attack onset when pain is severe. Many prescribers use both: CBD daily for prevention, low-dose THC as needed for acute attacks.
Can cannabis cause rebound headache?
Unlike triptans, NSAIDs and opioids, cannabis does not appear to cause medication overuse headache (MOH) at standard medicinal doses. This is one of its significant advantages for chronic migraine sufferers who are trying to avoid the MOH cycle.
Can I use cannabis alongside my triptans?
Cannabis and triptans work by complementary mechanisms and can generally be used together. Some patients find they need lower triptan doses when they use cannabis preventively. Discuss with your prescriber.
What is the best cannabis strain for migraine?
Caryophyllene-dominant strains (OG Kush, GSC, AK-47) are most commonly used for migraine due to caryophyllene’s direct CB2 anti-inflammatory and CGRP-modulatory effects. For prevention, any CBD-dominant preparation is appropriate. For acute use, indica-dominant hybrids with myrcene and caryophyllene are preferred.
Can cannabis help with migraine aura?
Preclinical data suggests endocannabinoids can inhibit cortical spreading depression (the mechanism of aura). Anecdotal patient reports suggest CBD taken at aura onset may reduce aura duration and prevent progression to headache in some patients. This is an area of active research.